Cat. No.: DAB-0012218
Product Information | |
---|---|
Clonality | Monoclonal |
Host Species | Rabbit |
Product Description | Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Thr72 of human Beclin-1, Leu210 of human Rubicon, Lys630 of PI3 kinase class III, and Gly502 of human UVRAG. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly825 of human PIK3R4 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Gene Description | LC3-associated phagocytosis is a process at the crossroads between autophagy and phagocytosis in which uptake of extracellular particles into phagophores utilizes components of the autophagic machinery and is targeted to the lysosome for degradation. Activation of LAP by infectious agents through engagement of pathogen receptors like Toll-like receptors are important in immune regulation and host defense. While autophagosomes and LAP phagophores both express lipidated LC3, autophagosomes are double membrane vesicles while the phagophores in LAP are single membrane. While LAP shares some components of canonical autophagy, there are some distinct differences. Both autophagy and LAP require PI3 Kinase Class III as well as the regulatory protein PIK3R4 and Beclin-1. However, while canonical autophagy requires Atg14 and Ambra-1 in this complex, LAP requires Rubicon and UVRAG. This complex, known as the LAPosome, activates PI3KC3 and triggers nicotinamide adenine dinucleotide phosphate oxidase 2, generating reactive oxygen species for phagophore maturation. The expression of Rubicon in this complex has emerged as a defining characteristic of LAP. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.